Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.

Bhargava HK, Leo P, Elliott R, Janowczyk A, Whitney J, Gupta S, Fu P, Yamoah K, Khani F, Robinson BD, Rebbeck TR, Feldman M, Lal P, Madabhushi A.

Clin Cancer Res. 2020 Mar 5. doi: 10.1158/1078-0432.CCR-19-2659. [Epub ahead of print]

PMID:
32139401
2.

Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, Spratt DE, Vidal AC, Lin D, Hitchins MP, You S, Freeman MR, Yamoah K, Davicioni E, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec 16. doi: 10.1038/s41391-019-0197-3. [Epub ahead of print]

PMID:
31844180
3.

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA.

J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058.

PMID:
31805523
4.

Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.

Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, Gerke TA.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):246-253. doi: 10.1158/1055-9965.EPI-19-0407. Epub 2019 Nov 22.

PMID:
31757784
5.

Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer.

Gerke T, Awasthi S, Yamoah K.

JAMA Oncol. 2019 Oct 31. doi: 10.1001/jamaoncol.2019.4497. [Epub ahead of print] No abstract available.

PMID:
31670755
6.

Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study.

Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Dadzie MA, Fink A, Naghavi AO, Abrahams A, Mensah JE, Sasu E, Tagoe SN, Dhillon J, Johnstone PAS, Yamoah K.

Am J Clin Oncol. 2019 Dec;42(12):937-944. doi: 10.1097/COC.0000000000000589.

7.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
8.

Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study.

Awasthi S, Gerke T, Williams VL, Asamoah F, Fink AK, Balkrishnan R, Park JY, Yamoah K.

Cancer Control. 2019 Jan-Dec;26(1):1073274819837184. doi: 10.1177/1073274819837184.

9.

Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy.

Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA.

Semin Radiat Oncol. 2019 Apr;29(2):111-125. doi: 10.1016/j.semradonc.2018.11.003. Review.

PMID:
30827449
10.

Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):570-577. doi: 10.1158/1055-9965.EPI-18-0812. Epub 2018 Nov 9.

11.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

12.

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.

Lancet Oncol. 2018 Nov;19(11):1504-1515. doi: 10.1016/S1470-2045(18)30528-X. Epub 2018 Oct 10. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

13.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

14.

Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience.

Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Venkat PS, Fink AK, Naghavi AO, Abrahams A, Mensah JE, Sasu E, Tagoe SNA, Johnstone PAS, Yamoah K.

J Glob Oncol. 2018 Jul;4:1-13. doi: 10.1200/JGO.17.00234.

15.

African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015.

Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K.

Cancer Med. 2018 May;7(5):2160-2171. doi: 10.1002/cam4.1451. Epub 2018 Mar 30.

16.

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.

Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx084.

17.

Modes of carbon fixation in an arsenic and CO2-rich shallow hydrothermal ecosystem.

Callac N, Posth NR, Rattray JE, Yamoah KKY, Wiech A, Ivarsson M, Hemmingsson C, Kilias SP, Argyraki A, Broman C, Skogby H, Smittenberg RH, Fru EC.

Sci Rep. 2017 Oct 31;7(1):14708. doi: 10.1038/s41598-017-13910-2.

18.

Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.

Echevarria MI, Naghavi AO, Abuodeh YA, Ahmed KA, Chevere C, Fernandez D, Yamoah K.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):378-382. doi: 10.1016/j.ijrobp.2017.04.002. Epub 2017 Apr 11.

PMID:
28871987
19.

miRNAs associated with prostate cancer risk and progression.

Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G.

BMC Urol. 2017 Mar 20;17(1):18. doi: 10.1186/s12894-017-0206-6. Review.

20.

Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.

Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB.

Cancer. 2017 Jun 15;123(12):2240-2247. doi: 10.1002/cncr.30580. Epub 2017 Jan 31.

21.

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy.

Echevarria MI, Naghavi AO, Venkat PS, Abuodeh YA, Chevere C, Yamoah K.

J Contemp Brachytherapy. 2016 Oct;8(5):386-390. Epub 2016 Nov 2.

22.

Predicting Prostate Cancer Recurrence After Radical Prostatectomy.

Jeffers A, Sochat V, Kattan MW, Yu C, Melcon E, Yamoah K, Rebbeck TR, Whittemore AS.

Prostate. 2017 Feb;77(3):291-298. doi: 10.1002/pros.23268. Epub 2016 Oct 24. Erratum in: Prostate. 2017 Jun;77(8):934.

23.

Proton beam therapy: clinical utility and current status in prostate cancer.

Yamoah K, Johnstone PA.

Onco Targets Ther. 2016 Sep 16;9:5721-5727. eCollection 2016. Review.

24.

Treatment delays, race, and outcomes in head and neck cancer.

Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ.

Cancer Epidemiol. 2016 Dec;45:18-25. doi: 10.1016/j.canep.2016.09.005. Epub 2016 Sep 22.

PMID:
27664388
25.

Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies.

Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ.

Cancer. 2016 Nov 15;122(22):3529-3537. doi: 10.1002/cncr.30212. Epub 2016 Aug 1.

26.

The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.

Yamoah K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, Spangler E, Park JY, Whittemore A, Rebbeck TR.

BMC Cancer. 2016 Jul 29;16:557. doi: 10.1186/s12885-016-2572-y.

27.

Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials.

Yamoah K, Showalter TN, Ohri N.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):737-45. doi: 10.1016/j.ijrobp.2015.07.2284. Epub 2015 Oct 19. Review.

28.

Efficient entry of cell-penetrating peptide nona-arginine into adherent cells involves a transient increase in intracellular calcium.

Melikov K, Hara A, Yamoah K, Zaitseva E, Zaitsev E, Chernomordik LV.

Biochem J. 2015 Oct 15;471(2):221-30. doi: 10.1042/BJ20150272. Epub 2015 Aug 13.

29.

Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM.

J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20.

30.

Corrigendum: "Training Global Oncologists: Addressing the Global Cancer Control Problem".

Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Martei Y, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM.

Front Oncol. 2015 Jun 10;5:133. doi: 10.3389/fonc.2015.00133. eCollection 2015.

31.

Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.

Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V, Werner-Wasik M, Evans JJ, Kim L, Glass J, Farrell C, Andrews DW, Shi W.

J Neurooncol. 2015 Sep;124(2):215-21. doi: 10.1007/s11060-015-1825-y. Epub 2015 May 30.

PMID:
26024653
32.

Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold.

Eldredge-Hindy HB, Duffy D, Yamoah K, Simone NL, Skowronski J, Dicker AP, Anne PR.

Pract Radiat Oncol. 2015 May-Jun;5(3):162-8. doi: 10.1016/j.prro.2014.10.002.

PMID:
25957186
33.

Training global oncologists: addressing the global cancer control problem.

Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM.

Front Oncol. 2015 Apr 8;5:80. doi: 10.3389/fonc.2015.00080. eCollection 2015. Review. No abstract available. Erratum in: Front Oncol. 2015;5:133.

34.

African-american race is a predictor of seminal vesicle invasion after radical prostatectomy.

Yamoah K, Walker A, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Dicker AP, Rebbeck TR, Lal P.

Clin Genitourin Cancer. 2015 Apr;13(2):e65-72. doi: 10.1016/j.clgc.2014.08.012. Epub 2014 Oct 25.

35.

African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Kattan M, Dicker AP, Rebbeck TR.

Urol Oncol. 2015 Feb;33(2):70.e15-22. doi: 10.1016/j.urolonc.2014.07.005. Epub 2014 Oct 7.

36.

Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.

Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Brachytherapy. 2014 Sep-Oct;13(5):456-64. doi: 10.1016/j.brachy.2014.04.003. Epub 2014 Jun 18.

PMID:
24953945
37.

A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.

Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196. Review.

38.

Spine Stereotactic Body Radiation Therapy Residual Setup Errors and Intra-Fraction Motion Using the Stereotactic X-Ray Image Guidance Verification System.

Yamoah K, Zaorsky NG, Siglin J, Shi W, Werner-Wasik M, Andrews DW, Dicker AP, Bar-Ad V, Liu H.

Int J Med Phys Clin Eng Radiat Oncol. 2014 Feb;3(1):1-8. doi: 10.4236/ijmpcero.2014.31001.

39.

High dose rate brachytherapy boost for prostate cancer: a systematic review.

Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB.

Cancer Treat Rev. 2014 Apr;40(3):414-25. doi: 10.1016/j.ctrv.2013.10.006. Epub 2013 Oct 26. Review.

PMID:
24231548
40.

Information shared with mothers prior to caesarean section: a national audit of compliance with recommended information.

Ghosh A, Yamoah K, Pring D.

J Obstet Gynaecol. 2013 Jul;33(5):471-3. doi: 10.3109/01443615.2013.776025. Erratum in: J Obstet Gynaecol. 2013 Oct;33(7):755. Gosh, A [corrected to Ghosh, A].

PMID:
23815199
41.

Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes.

Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J.

BMC Cancer. 2013 Jan 16;13:23. doi: 10.1186/1471-2407-13-23.

42.

Heterotopic pregnancy: should we instrument the uterus at laparoscopy for ectopic pregnancy.

Yamoah KK, Girn Z.

BMJ Case Rep. 2012 Nov 19;2012. pii: bcr2012006497. doi: 10.1136/bcr-2012-006497.

43.

SU-E-T-166: Use of an in Vivo Dosimeter to Assess the Implications of Daily Prostate Rotations.

Studenski M, Gardner S, Yamoah K, Buzurovic I, Showalter T, Den R.

Med Phys. 2012 Jun;39(6Part12):3741. doi: 10.1118/1.4735224.

PMID:
28517846
44.

Impact of race on biochemical disease recurrence after prostate brachytherapy.

Yamoah K, Stone N, Stock R.

Cancer. 2011 Dec 15;117(24):5589-600. doi: 10.1002/cncr.26183. Epub 2011 Jun 20.

45.

A large epulis in pregnancy.

Yamoah KK, Lindow S, Karsai L.

J Obstet Gynaecol. 2009 Nov;29(8):761-2. doi: 10.3109/01443610903215407. No abstract available.

PMID:
19821674
46.

Characterization of the human COP9 signalosome complex using affinity purification and mass spectrometry.

Fang L, Wang X, Yamoah K, Chen PL, Pan ZQ, Huang L.

J Proteome Res. 2008 Nov;7(11):4914-25. doi: 10.1021/pr800574c. Epub 2008 Oct 14.

47.

Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail.

Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, Pan ZQ.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12230-5. doi: 10.1073/pnas.0806155105. Epub 2008 Aug 22.

48.

Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss.

Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4289-94. doi: 10.1073/pnas.0712395105. Epub 2008 Mar 10.

49.

High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence.

Yamoah K, Brebene A, Baliram R, Inagaki K, Dolios G, Arabi A, Majeed R, Amano H, Wang R, Yanagisawa R, Abe E.

Mol Endocrinol. 2008 May;22(5):1141-53. doi: 10.1210/me.2007-0460. Epub 2008 Jan 24.

50.

Bone loss in thyroid disease: role of low TSH and high thyroid hormone.

Abe E, Sun L, Mechanick J, Iqbal J, Yamoah K, Baliram R, Arabi A, Moonga BS, Davies TF, Zaidi M.

Ann N Y Acad Sci. 2007 Nov;1116:383-91. Review.

PMID:
18083940

Supplemental Content

Loading ...
Support Center